latrepirdine has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawker, DD; Jansen Labby, K; Mataka, JJ; Silverman, RB; Trippier, PC | 1 |
| Britt, J; De Jesús-Cortés, H; Drawbridge, J; Estill, SJ; Huntington, P; McKnight, SL; Melito, LM; Morlock, L; Naidoo, J; Pieper, AA; Ready, JM; Tesla, R; Tran, S; Wang, G; Williams, NS; Xu, P | 1 |
1 review(s) available for latrepirdine and Parkinson Disease
| Article | Year |
|---|---|
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate | 2013 |
1 other study(ies) available for latrepirdine and Parkinson Disease
| Article | Year |
|---|---|
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caenorhabditis elegans; Carbazoles; Dopaminergic Neurons; Dose-Response Relationship, Drug; Hippocampus; Indoles; Mice; Mice, Inbred C57BL; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2012 |